CD4 and hyperinsulinemic hypoglycemia, familial, 4: In two small clinical trials (NCT01370018 and NCT01731691), we previously showed that subjects infused weekly for 9 weeks with FDA-approved α1PI plasma products exhibited a dramatic, sustained increase in circulating CD4+ T cell numbers and/or an increase in CD4/CD8 T cell ratios in individuals infected with HIV-1 and, in parallel, in uninfected clinic patients with an α1PI genetic deficiency (Pi-ZZ) who were initiating treatment (17, 24).